Penile Cancer Clinical Trial
Official title:
Activity and Tolerability of Maintenance Avelumab Immunotherapy After First Line Polychemotherapy Including Platinum in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma
Patients with unresectable locally advanced or metastatic squamous cell penile carcinoma (SPC) who are in response or with stable disease after first line platinum containing polychemotherapy who meet the inclusion/exclusion criteria will be offered to take part in the study. The patients may be pre-screened at the time of the 1st line chemotherapy. In order for patients to be enrolled, the investigator must have carried out a radiological assessment of the disease during first line systemic treatment (a maximum of between 3 and 6 cycles): the cancer must be controlled. Patients with disease progression cannot be included in the PULSE study as this is a maintenance study. After inclusion, Avelumab will be administered at a dose of 10 mg/kg, at a frequency of once every 2 weeks with appropriate supportive care.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03686332 -
PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study
|
Phase 2 | |
| Completed |
NCT05518201 -
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
|
Phase 1 | |
| Recruiting |
NCT04708470 -
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04357873 -
Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
|
Phase 2 | |
| Terminated |
NCT00058448 -
S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)
|
Phase 2 | |
| Recruiting |
NCT02817958 -
Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis
|
Phase 2 | |
| Completed |
NCT02280811 -
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
|
Phase 2 | |
| Recruiting |
NCT02994758 -
Development of Diagnostics and Treatment of Urological Cancers
|
N/A | |
| Completed |
NCT00019110 -
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
|
Phase 1 | |
| Completed |
NCT04574427 -
INtra-operative Evaluation of a Novel FLUorescENt C-mEt Tracer in Penile and Tongue
|
||
| Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|
||
| Recruiting |
NCT05946993 -
Linking In With Advice and Supports for Men Impacted by Metastatic Cancer
|
N/A | |
| Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
| Recruiting |
NCT05686226 -
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
|
Phase 2 | |
| Completed |
NCT05376202 -
Image Guided Penile Cancer Surgery
|
Phase 1 | |
| Recruiting |
NCT05264337 -
Lymphedema After Urologic Surgery
|
||
| Completed |
NCT01209325 -
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
|
Phase 2 | |
| Recruiting |
NCT05592639 -
VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer
|
N/A | |
| Completed |
NCT00066391 -
Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06353906 -
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
|
Phase 2 |